Q-omics provides the consensus-scored HTRA1 profile across patient tissues and cancer cell-line models. HTRA1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HTRA1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, HTRA1 protein abundance shows 20,184 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, HNSC, and BRCA as cancer lineages where HTRA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTRA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTRA1 survival associations across molecular data types. HTRA1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTRA1 RNA expression–survival associations across cancer types. High HTRA1 expression shows unfavorable associations in UVM, BLCA, STAD, ACC and HNSC, but favorable associations in DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for HTRA1 RNA expression.
This table summarizes HTRA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for HTRA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTRA1 shows lower tumor expression in KICH, UCEC, KIRP and BLCA and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher HTRA1 RNA expression in tumor versus normal tissue (log2 FC = +2.998, t-test p < 0.001).
This table shows molecular features associated with HTRA1 in patient tissues and cancer cell lines. In patient samples, HTRA1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, HTRA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
